AVITA Medical (RCEL) Morgan Stanley 24th Annual Global Healthcare Conference summary
Event summary combining transcript, slides, and related documents.
Morgan Stanley 24th Annual Global Healthcare Conference summary
16 Sep, 2026Leadership and operational focus
New CEO prioritized solving fixable issues and maximizing company potential, emphasizing focus and execution over the past 9-10 months.
Streamlined operations by eliminating distractions, implementing effective compensation plans, and ensuring organizational alignment.
Consistent internal and external messaging and placing the right people in key roles have driven recent growth.
Growth strategy and commercial execution
Achieved strong sequential growth over the last three quarters, leading to raised 2026 guidance.
Focused on deepening penetration within existing 200 accounts, with significant room for growth across three product lines.
Sales team efficiency and effectiveness are enhanced by offering a portfolio approach, building trust and consultative relationships with customers.
Product adoption and market opportunity
Barriers to adoption include the need for clinical, workflow, and economic arguments to change physician habits.
RECELL demonstrates clinical benefits such as faster healing, better pigmentation, and a 36% reduction in length of stay.
Expansion into trauma and surgical repair is underway, but burn remains the core focus due to high penetration potential.
Latest events from AVITA Medical
- PermeaDerm delivers a 70% cost reduction, workflow benefits, and clinical outcomes on par with allograft.RCEL
KOL event - 2026 guidance raised to $86–$89M, with Q4 breakeven targeted and strong Q2 revenue growth.RCEL
Investor update - Revenue growth, margin stability, and product adoption drive confidence in sustained expansion.RCEL
Canaccord Genuity's 46th Annual Growth Conference - Q2 2026 revenue up 18% year-over-year; guidance raised, but going concern risk remains.RCEL
Q2 2026 - Sequential revenue growth, strong margins, and reaffirmed guidance signal renewed momentum.RCEL
Status update - Revenue up 4% to $19.3M, net loss narrows, but going concern risk remains.RCEL
Q1 2026 - Shareholders will vote on director elections, compensation, equity grants, and key capital changes.RCEL
Proxy filing - 2026 guidance targets $80–$85M revenue, with growth, reimbursement clarity, and new financing.RCEL
Status update - Q2 2024 revenue up as much as 44% to $19.5M; 2024 guidance set at $68–$70M.RCEL
Q2 2024